Recent Updates
Recently added Catalysts
XAIR Positive Sentiment

Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference

Key Takeaway: Beyond Air, Inc. will participate in the 2026 Cantor Global Healthcare Conference from September 9-11, 2026. The management team will host a fireside chat on September 10 at 3:55 PM EDT, which will be available via a live webcast. The company focuses on nitric oxide therapies for respiratory and neurological conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prestigious healthcare conference
  • Opportunity for one-on-one meetings with investors
  • Showcases commitment to improving patient lives
  • Live webcast increases accessibility for stakeholders

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~5 mo
High dilution risk
Lead asset
Nitric Oxide
Phase 3 · Bronchiolitis

Full Press Release Details

GARDEN CITY, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that its management team will participate in the 2026 Cantor Global Healthcare Conference, which is being held at the Waldorf Astoria New York, New York on September 9-11, 2026.
Fireside Chat Details: Date: Thursday, September 10 th Time: 3:55 PM EDT Webcast Link: A live webcast of the fireside chat will be available on the Events section of the Company’s website, https://www.beyondair.net/news-events/events. Following the live presentation, a replay of the webcast will be available on the Company's website for 90 days.
If you are interested in requesting a one-on-one meeting at the conference, please contact your Cantor representative to schedule accordingly.
About Beyond Air, Inc. Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net.

Frequently Asked Questions

When is the 2026 Cantor Global Healthcare Conference?

The conference will be held from September 9-11, 2026.

What time is Beyond Air's fireside chat?

The fireside chat is scheduled for September 10 at 3:55 PM EDT.

How can I access the webcast of the fireside chat?

The live webcast will be available on Beyond Air's website in the Events section.

What is the focus of Beyond Air's therapies?

Beyond Air focuses on nitric oxide therapies for respiratory illnesses and neurological disorders.

Has Beyond Air received any regulatory approvals?

Yes, Beyond Air has received FDA approval and CE Mark for its LungFit PH system.

Last updated: Sep 2, 2026